ResMed Inc.

RMD · NYSE · Stock · Healthcare

$233.21

-0.78% today

Delayed price, 2026-10-14 17:14 UTC

What ResMed does

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Key facts

Sector

Healthcare

Industry

Medical Instruments & Supplies

Market cap

$32.80B

P/E (ttm)

22.4

Forward P/E

17.6

Dividend yield

1.12%

Beta

0.75

Profit margin

26.9%

Employees

11,370

Headquarters

San Diego, CA, United States

Exchange

NYSE

Website

www.resmed.com

Performance

1 Month

+3.7%

3 Months

+17.2%

6 Months

+2.2%

1 Year

-13.0%

5 Years

-8.5%

$180.2752-week range$277.67

Biggest setback — last 12 months

-30.6%

2 Feb 2026 → 15 Jun 2026

Fell from $271.63 to $188.63 — its sharpest sustained decline this year.

Biggest run-up — last 12 months

+27.4%

15 Jun 2026 → 24 Aug 2026

Ran from $188.63 to $240.33 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Above long-term trend

Price sits above its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.

Horizon	Bear case (−1σ)	Base case	Bull case (+1σ)
1 Month	$214.71 (-7.9%)	$233.21	$253.29 (+8.6%)
3 Months	$202.11 (-13.3%)	$233.21	$269.09 (+15.4%)
6 Months	$190.47 (-18.3%)	$233.21	$285.53 (+22.4%)
12 Months	$175.15 (-24.9%)	$233.21	$310.50 (+33.1%)

Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 28.6%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Boston Scientific Corporation

$42.45 · -2.0%

BDX

Becton, Dickinson and Company

$187.44 · +0.0%

Edwards Lifesciences Corporation

$85.96 · +0.8%

IDXX

IDEXX Laboratories, Inc.

Recent headlines

ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings? — StockStory ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures — Insider Monkey Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)? — Simply Wall St.Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest — StockStory ResMed Stock: Is RMD Underperforming the Healthcare Sector? — Barchart ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles — Insider Monkey

Recent insider activity

Sold 9,982 shares at $226.33 — Farrell Michael J., Chairman and CEO · 2026-10-08

Acquired 6,461 shares — Leong Justin, Chief Product Officer · 2026-10-01

Acquired 3,230 shares — Rider Michael J, Global General Counsel · 2026-10-01

Acquired 13,547 shares — Farrell Michael J., Chairman and CEO · 2026-10-01

Acquired 9,072 shares — Bloomer Aaron, Chief Financial Officer · 2026-10-01

Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

What is a stock? Understanding risk and reward Why diversification matters

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.